[1] Xiao, S., F. Shi, …, Y. Dai, M. Lu#. Characterization of the generic mutant p53-rescue compounds in a broad range of assays. Cancer Cell, 2024, 42(3): 325-327.

[2] Song, H., S. Xiao, J. Wu, M. Lu#. Drugging p53: Barriers, Criteria, and Prospects. Cancer Discov, 2024, 14(11): 2055-2060.

[3] Song, H., J. Wu, …, S. Zhang, M. Lu#. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Science Translational Medicine, 2023, 15(690): eabn9155.

[4] Chen, S., J.-L. Wu, …, S.-J. Chen, M. Lu#. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell, 2021, 39(2): 225-239.e8.

[5] Tang Y, Song H, …, Liu F, Wu Y, Lu M#. Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Reports 2022;39(2):110622.

[6] Liang, Y., Q. An, …, X. Cao, M. Lu#. AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity. J Med Chem, 2023, 66(24): 16579-16596.

[7] Wang, Z., Y. Zhao, …, H. Yang, M. Lu#. Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 Mpro. Signal Transduction and Targeted Therapy, 2021, 6(1): 214.


[8] Lu, M#., J. Zak, …, Christopher J. Schofield and X. Lu. A Code for RanGDP Binding in Ankyrin Repeats Defines a Nuclear Import Pathway. Cell, 2014, 157(5): 1130-1145.


[9] Lu, M#., H. Breyssens, …, C. R. Goding and X. Lu. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell, 2013, 23(5): 618-633.


[10] Lu, M#., M. R. Muers and X. Lu. Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding. Nature Reviews Molecular Cell Biology, 2016, 17(8): 523-532.

[1] Xiao S*, Shi F*, Song H*, Cui J*...Dai Y#, Lu M#.Cancer Cell 2024;42(3):325-327.
[2] Song H*, Wu J*, Tang Y*, Dai Y* ... Lu M#. Science Translational Medicine 2023;15:eabn9155.
[3] Chen S*, Wu J*, Liang Y* ... Lu X#, Chen S#, Lu M#. Cancer Cell 2021;39(2):225-239.e8.
[4] Tang Y*, Song H*, Wang Z*, Xiao S* ... Liu F#, Wu Y#, Lu M#. Cell Reports 2022;39(2):110622.
[5]Liang Y*, An Q*, Song H*, Tang Y*...Lu M#. Journal of Medicinal Chemistry 2023, 66:16579-96.
[6] Wang Z*, Zhao Y*, Wang Q*, Xing Y* ... Zhang L#, Yang H#, Lu M#.Signal Transduction and Targeted Therapy 2021;6(1):214.
[7] Yan N*, Li Y*... Lu M#. EMBO Rep 2022;23(6):e54147.
[6]Yan Q*, Sun R*, Cui Z*... Lu M#, Zhu Y#, Fan C#. (2022). Nano Today 2022;47:101649.
[7]Wu J*, Li Y*, Wu J*...Lu M#. Clin Transl Med 2021;11(11):e593.
[8] Lu M ...Lu X#. Cell 2014, 157:1130-45
[9] Lu M ...Lu X#. Cancer Cell 2013, 23:618-33.
[10] Lu M ...Lu X#. Nat Rev Mol Cell Biol 2016, 17:523-32

1、Lu, Min; Wu, Jiale; Song, Huaxin. PANDA as a novel therapeutic, PCT/CN2018/085190. The patent has entered China (2020071600684380), US (16959906), EU (EP18898022.1), JP (3148-PCT-JP), AU (2018399726), and CA(0146523-00002).

2、Lu, Min; Wu, Jiale; Song, Huaxin. mp53 rescue compounds and methods of treating a p53 disorder, PCT/CN2019/070117. The patent has entered China (2020071600808010), US(16959894), EU (EP19736093.6), JP (3147-PCT-JP), AU (2019205062), and CA(0146523-00001).

3、Lu, Min; Liang, Ying; Xiao, Shujun; Song, Huaxin. Dual-specificity p53 rescue compound and method of use. 202110659536.4.

4、Lu, Min; Song, Huaxin. A method to screen p53-mutant cancer patients that are applicable for the p53 rescue drugs. 202110659578.8.

5、Lu, Xin; Lu, Min. iASPP phosphorylation and metastatic potential. WIPO, WO 2013/131019 A1

1、Arsenic Trioxide in Refractory Solid Tumors with Rescuable p53 Mutation (https://www.clinicaltrials.gov/ct2/show/NCT04869475)

2、Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS。(https://www.clinicaltrials.gov/ct2/show/NCT03855371)

3、Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations (https://www.clinicaltrials.gov/ct2/show/NCT04906031)

4、Introduction in TP53 Trust (http://tp53.co.uk/interview-with-min-lu/)

5、Introduction in AntiCancer Fund (https://www.anticancerfund.org/en/blog/latest-news-about-drug-repurposing-oncology-4)